tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Maury Raycroft, 83 are a BUY (79.81%), 21 are a HOLD (20.19%).
Analyst Maury Raycroft, currently employed at JEFFERIES, carries an average stock price target met ratio of 51.13% that have a potential upside of 35.97% achieved within 146 days.
Maury Raycroft’s has documented 227 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BCRX, BioCryst Pharmaceuticals at 03-Nov-2023.
Analyst best performing recommendations are on VERA (VERA THERAPEUTICS).
The best stock recommendation documented was for ALNY (ALNYLAM PHARMACEUTICALS) at 9/18/2017. The price target of $102 was fulfilled within 2 days with a profit of $26 (34.21%) receiving and performance score of 171.05.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$15
$12.86 (600.93%)
$25
8 days ago
(12-Dec-2024)
0/2 (0%)
$12.83 (591.24%)
Buy
$10
$7.86 (367.29%)
$10
10 days ago
(10-Dec-2024)
0/6 (0%)
$7.73 (340.53%)
Buy
1 months 1 days ago
(19-Nov-2024)
1/2 (50%)
$-33.5 (-73.63%)
246
Hold
$4
$1.86 (86.92%)
$5
1 months 5 days ago
(15-Nov-2024)
2/4 (50%)
$0.42 (11.73%)
25
Buy
$25
$22.86 (1068.22%)
$110
6 months 7 days ago
(13-Jun-2024)
2/3 (66.67%)
$17.91 (252.61%)
348
What Year was the first public recommendation made by Maury Raycroft?
